Beiträge
Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
/in International Publications /von 2020-11-22 / Biomedicines 2020 Nov;8(11)Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-07-23 / Biomedicines 2020 Jul;8(8)Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, Newcastle Disease Virus /von 2020-05-19 / Medicines (Basel) 2020 May;7(5)Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2020-03-16 / Biomedicines 2020 Mar;8(3)New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2020-03-06 / Biomedicines 2020 Mar;8(3)Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
/in International Publications, Newcastle Disease Virus /von 2017-05-20 / Int J Mol Sci 2017 May;18(5)Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
/in International Publications, Newcastle Disease Virus /von 2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
- Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma; a single center phase I/II trial
- MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells